SCHEDULE: Morgan Stanley Reports Stake in Jasper Therapeutics

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed a Schedule 13G indicating their beneficial ownership of Jasper Therapeutics, Inc. common stock.

Summary

• Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed an amendment to their Schedule 13G regarding their beneficial ownership of Jasper Therapeutics, Inc. common stock.
• As of March 31, 2026, Morgan Stanley reported beneficial ownership of 1,333,220 shares, representing 4.8% of the class of securities.
• Morgan Stanley Capital Services LLC reported beneficial ownership of 1,294,420 shares, representing 4.6% of the class of securities.
• Both entities have stated that, as of the date of the filing, they have ceased to be the beneficial owner of more than five percent of the class of securities.
• The filing is an amendment to a previous filing and indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing, as it indicates a reduction in beneficial ownership by significant institutional players, which could be interpreted as a lack of conviction or a strategic exit from a portion of their stake.

Positives

• Morgan Stanley and its subsidiary have filed the required disclosure, indicating compliance with regulatory requirements.
• The filing confirms that the entities are not holding shares with the intent to influence or control Jasper Therapeutics, Inc.

Negatives

• Both Morgan Stanley and Morgan Stanley Capital Services LLC have ceased to be beneficial owners of more than five percent of Jasper Therapeutics, Inc. common stock, suggesting a reduction in their stake or a shift in reporting thresholds.
• The specific reasons for ceasing to be beneficial owners of more than five percent are not detailed, which could imply a sale of shares or a change in their investment strategy.

Risks

• The reduction in beneficial ownership by significant entities like Morgan Stanley could be interpreted by the market as a lack of confidence or a strategic divestment, potentially impacting Jasper Therapeutics' stock price.
• While not explicitly stated as a risk, the decrease in holdings by institutional investors can sometimes precede broader market sentiment shifts regarding the company's prospects.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Jasper Therapeutics, Inc. It solely reports on beneficial ownership as of a specific date.

Management Comments

• "As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities."
• "As of the date hereof, Morgan Stanley Capital Services LLC has ceased to be the beneficial owner of more than five percent of the class of securities."
• "In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors crossing or falling below the 5% beneficial ownership threshold. The cessation of beneficial ownership above 5% by Morgan Stanley entities in Jasper Therapeutics, Inc. suggests a potential shift in institutional holdings within the biotechnology sector, a field often characterized by significant investment and volatility.

Stakeholder Impact

• Shareholders may interpret the reduction in beneficial ownership by Morgan Stanley entities as a signal of reduced institutional support or a potential sell-off, which could influence share price.
• The market may view this filing as a sign of reduced institutional interest in Jasper Therapeutics, Inc.

Next Steps

• Morgan Stanley and Morgan Stanley Capital Services LLC will continue to monitor their beneficial ownership levels in Jasper Therapeutics, Inc. and file amendments to Schedule 13G as required by SEC regulations.

Key Dates

Recommendation

The filing is a routine disclosure of beneficial ownership and does not provide operational or financial performance data for Jasper Therapeutics, Inc. The reduction in stake by Morgan Stanley entities is noted, but without further context on the company's performance or strategic direction, a 'hold' recommendation is prudent, awaiting more substantive updates.

Keywords

Schedule 13G, Jasper Therapeutics, Morgan Stanley, Morgan Stanley Capital Services LLC, Beneficial Ownership, Common Stock, SEC Filing, Amendment